Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Trimetazidine Hydrochloride I.P. 35mg Tablets
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹199/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Trizapime is a specialized pharmaceutical formulation containing Trimetazidine Hydrochloride, primarily used in the management of angina pectoris and other cardiovascular conditions. Trimetazidine works by improving the efficiency of energy metabolism in heart cells, thereby reducing the heart's oxygen demand, especially during periods of stress. This helps to maintain normal heart function and alleviates chest pain and discomfort associated with angina.
Trizapime is commonly prescribed for patients with chronic stable angina to reduce the frequency and severity of angina attacks. It can also be used in combination with other cardiovascular medications for a more comprehensive approach to managing heart disease. The medication works by ensuring that the heart’s cells can maintain their energy production in the face of reduced oxygen, improving overall cardiac performance.
Trizapime is well-tolerated by most patients and is generally considered safe when used as directed by a healthcare provider. It is available in tablet form, making it convenient for both outpatient and long-term care treatments. The recommended dosage is typically 35 mg once or twice daily, depending on the severity of the condition and as prescribed by a healthcare professional.
Possible side effects include dizziness, nausea, headache, gastrointestinal disturbances, or allergic reactions. Consult a healthcare provider if side effects persist.
Trizapime is indicated for the management of chronic stable angina and to improve the functional capacity of patients with angina pectoris.
Use Trizapime only as directed by a healthcare professional. Do not exceed the recommended dose. Discontinue use if allergic reactions occur and consult your doctor.
Store in a cool, dry place at 15°C to 30°C, away from direct sunlight. Keep out of reach of children.
Composition : Trimetazidine 20 mg tablet
Composition : Trimetazidine 60 mg tablet
Composition : Clopidogrel (75mg) + Aspirin (75mg) Tablet
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : L-Arginine (3gm) + Proanthocyanidin (75mg) sachet
Composition : L-Methyl Folate (1mg) + Methylcobalamin (1500mcg) + Pyridoxal-5-phosphate (0.5mg) + Docosahexaenoic Acid (DHA) (200mg)
Composition : Bosentan 62.5mg Tablet
Composition : Carvedilol 12.5 tablet
Composition : Carvedilol 6.25mg Tablet
Composition : Carvedilol CR 10mg Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Trimetazidine Tablets have strong demand in the cardiology and chronic cardiovascular care segment, making them a valuable product for pharma distributors, wholesalers, and franchise partners. It is widely prescribed for stable angina and ischemic heart disease support therapy, ensuring consistent long-term prescription-based demand.
Medical distributors and agencies benefit from the chronic and long-duration usage pattern of cardiac medications. Helps improve myocardial energy metabolism under ischemic conditions Commonly used as add-on therapy in stable angina patients Frequently prescribed by cardiologists and physicians for long-term management Supports patients with chest pain and exercise-induced angina symptoms Ensures repeat monthly prescriptions due to chronic therapy use Strong demand in urban hospitals and cardiology clinics This makes it a stable and high-retention product in the cardiovascular segment.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Trimetazidine Hydrochloride 35 mg Tablets with monopoly rights, promotional support, quality manufacturing, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and franchise partners benefit from steady chronic-care demand, repeat prescriptions, strong cardiology market penetration, and consistent monthly sales due to long-term patient therapy requirements.
Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete cardiovascular product portfolio access to grow a strong presence in the cardiac care segment.